Clinical Trials Directory

Trials / Completed

CompletedNCT05847439

A Study to Evaluate the Absorption, Metabolism, and Excretion of [14C]BMS-986419 in Healthy Male Participants

A Phase 1, Single-center, Open-label Study of the Absorption, Metabolism, and Excretion of [14C]BMS-986419 in Healthy Male Participants

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
8 (actual)
Sponsor
Bristol-Myers Squibb · Industry
Sex
Male
Age
18 Years – 55 Years
Healthy volunteers
Accepted

Summary

The purpose of this study is to assess the pharmacokinetics (PK), metabolite profile, routes and extent of elimination, mass balance, as well as safety and tolerability of \[14C\]BMS-986419 in healthy male participants.

Conditions

Interventions

TypeNameDescription
DRUG[14C]BMS-986419Specified dose on specified days

Timeline

Start date
2023-05-05
Primary completion
2023-07-05
Completion
2023-07-05
First posted
2023-05-06
Last updated
2023-10-02

Locations

1 site across 1 country: United States

Regulatory

Source: ClinicalTrials.gov record NCT05847439. Inclusion in this directory is not an endorsement.

A Study to Evaluate the Absorption, Metabolism, and Excretion of [14C]BMS-986419 in Healthy Male Participants (NCT05847439) · Clinical Trials Directory